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Background: In some rheumatic diseases such as systemic lupus erythematosus (SLE), low serum complement
(‘hypocomplementaemia’) is a feature of active disease. However, the role of hypocomplementaemia in systemic
sclerosis (SSc) is unknown. We sought to determine the frequency, clinical associations and relationship to disease
activity of hypocomplementaemia in SSc.
Methods: The study included 1140 patients fulfilling the 2013 American College of Rheumatology criteria for SSc.
Demographic, serological and clinical data, obtained prospectively through annual review, were analysed using
univariable methods. Linear and logistic regression, together with generalised estimating equations, were used to
determine the independent correlates of hypocomplementaemia ever, and at each visit, respectively.
Results: At least one episode of hypocomplementaemia (low C3 and/or low C4) occurred in 24.1 % of patients
over 1893 visits; these patients were more likely to be seropositive for anti-ribonucleoprotein (OR = 3.8, p = 0.002),
anti-Ro (OR = 2.2, p = 0.002), anti-Smith (OR = 6.3, p = 0.035) and anti-phospholipid antibodies (OR = 1.4, p = 0.021)
and were more likely to display features of overlap connective tissue disease, in particular polymyositis (OR = 16.0,
p = 0.012). However, no association was found between hypocomplementaemia and either the European Scleroderma
Study Group disease activity score or any of its component variables (including erythrocyte sedimentation rate) in
univariate analysis. Among patients with SSc overlap disease features, those who were hypocomplementaemic
were more likely to have digital ulcers (OR = 1.6, p = 0.034), tendon friction rubs (OR = 2.4, p = 0.037), forced vital
capacity <80 % predicted (OR = 2.9, p = 0.008) and lower body mass index (BMI) (OR for BMI = 0.9, p < 0.0005) at
that visit, all of which are features associated with SSc disease activity and/or severity.
Conclusions: While hypocomplementaemia is not associated with disease activity in patients with non-overlap
SSc, it is associated with some features of increased SSc disease activity in patients with overlap disease features.
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Systemic sclerosis (SSc) or scleroderma is a systemic
autoimmune disorder of unknown aetiology associated
with substantial morbidity and mortality [1]. The hall-
mark pathological features of SSc are vasculopathy, in-
flammation and progressive perivascular and interstitial* Correspondence: m.nikpour@unimelb.edu.au
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include skin thickening, Raynaud’s phenomenon,
digital ulcers, gut involvement (gastro-oesophageal
reflux disease, intestinal hypomotility and pseudo-
obstruction), pulmonary arterial hypertension (PAH),
interstitial lung disease (ILD) and renal crisis [3]. An
‘SSc overlap’ syndrome is considered present when a
patient with SSc also has clinical and/or serological
evidence of one or more of systemic lupus erythematosus
(SLE), polymyositis, Sjögren’s syndrome or rheumatoid
arthritis [2].le is distributed under the terms of the Creative Commons Attribution 4.0
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tivity leads to irreversible organ damage. Activity reflects
features of the disease process that vary over time and
are potentially reversible with intervention or spontan-
eously. Quantifying active disease would assist clinicians
in assessment and management of disease activity, which
might in turn prevent damage and improve outcomes
[4]. Assessing disease activity is necessary for staging the
disease and predicting prognosis. It is also useful for
distinguishing between those patients requiring aggres-
sive treatment and those for whom symptomatic treat-
ment may be sufficient, as well as for monitoring
response to treatment.
In certain rheumatic diseases characterised by distinct
episodes of inflammation, such as SLE, validated measures
already exist to assist clinicians in the assessment of
disease activity [5]. There have been several endeavours to
develop disease activity criteria for SSc. The European
Scleroderma Study Group (EScSG) activity index was con-
structed on the basis of evaluation of features of a large
multicentre cohort of patients with SSc, compared with a
gold standard of disease activity assessment by three
experts [6–8]. Univariate analysis of symptoms, signs and
laboratory tests was performed to select single items that
were significantly associated with the consensus disease
activity score. The final index comprised ten components,
including clinical features such as arthritis, modified
Rodnan skin score (MRSS) and digital ulcers; patient-
reported changes in cardiopulmonary, skin and vascular
symptoms; and erythrocyte sedimentation rate (ESR)
[6, 7]. Hypocomplementaemia was also included [7, 8],
but it is not yet known whether low complement is
truly a marker of disease activity in SSc.
Various candidate serological markers have been pro-
posed to be related to disease activity in SSc, such as
soluble interleukin-2 receptor (sIL-2R), type III procol-
lagen aminopeptide (PIIINP) and von Willebrand fac-
tor propeptide [9–11]. However, in patients with SSc,
changes in these markers have not been reflected in
clinical responses to therapy. For example, chlorambu-
cil administration was followed by normalization of
sIL-2R levels but had no effect on disease activity [12].
Similarly, α-interferon administration resulted in a
decrease in PIIINP levels without any improvement in
disease activity assessed using a validated skin score,
grip strength, measurements of digital contractures,
Ritchie index, assessment of muscle weakness, and ten-
don friction rubs [13].
Low serum complement is a candidate serological
marker of disease activity in SSc. Aberrant activation of
the complement system is implicated in the pathogenesis
of a number of systemic autoimmune disorders [14]. For
example, in SLE, immune complex formation triggers
the complement cascade via the classical pathway, andthe resulting low concentrations of complement compo-
nents C3 and C4 are found in many patients with active
and severe SLE [15, 16]. It has been shown that the
manifestations of SSc are due to derangements in both
innate and adaptive immunity. The association of Toll-
like receptor (TLR) signalling variations with SSc suggests
that TLR pathways, and hence complement activation and
consumption, may play a role in the pathogenesis of SSc
[17]. However, unlike SLE, wherein low serum comple-
ment is a validated measure of disease activity, the re-
lationship between hypocomplementaemia and disease
activity in SSc is less clear.
The aim of this study was to evaluate the frequency of
hypocomplementaemia in a cohort of patients with SSc
and to evaluate which clinical and serological features
are significantly associated with hypocomplementaemia.
We hypothesised that hypocomplementaemia is associ-
ated with clinical features of disease activity such as
arthritis, tendon friction rubs, low body mass index
(BMI) (a marker of severe SSc gastrointestinal involve-




Patients were recruited from the Australian Scleroderma
Cohort Study, a prospective multi-centre cohort study of
risk factors for clinically important outcomes in SSc. All
patients fulfilled the 2013 American College of Rheuma-
tology classification criteria for SSc [18]. Patients were re-
cruited from multiple Australian centres that specialize in
the care of patients with SSc, which included St Vincent’s
Hospital and Monash Medical Centre, Victoria; Royal
Prince Alfred and St George Hospitals, New South Wales;
Sunshine Coast Rheumatology and Prince Charles Hos-
pital, Queensland; Royal Adelaide Hospital, The Queen
Elizabeth Hospital and Flinders Medical Centre, South
Australia; Royal Perth Hospital, Western Australia; and
Menzies Institute for Medical Research, Tasmania. The
study was approved by the human research ethics com-
mittees of each of the participating centres.
Consent was obtained from all patients prior to the
collection of demographic and disease-related data
(including clinical and laboratory data) according to a
standardized protocol at recruitment and at each sub-
sequent annual review. Patients were included if they
had at least one annual visit where complement levels
had been recorded, along with demographic, clinical
and laboratory data (see below).
Measurement of complement levels
C3 and C4 levels were measured prospectively at each
annual visit in the laboratories of each of the recruiting
centres using sera obtained at recruitment and at each
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plement levels were defined as being either normal or
low according to local laboratory standards. Patient visits
were then recorded as normocomplementaemic if the
patient had a normal C3 and C4 result or hypocomple-
mentaemic if the patient had a low C3 and/or C4.
Demographic, clinical and laboratory variables
All data were collected prospectively.
Data collected at recruitment
Demographic data collected at recruitment included age
at disease onset and age at recruitment. Disease onset
was defined according to the age at which the first non-
Raynaud’s phenomenon manifestation of SSc occurred.
Sex and race were also recorded; race was categorized as
white, Asian, Aboriginal or Torres Strait Islander, or other.
Disease duration was defined as the time elapsed from
disease onset to recruitment, and length of follow-up was
defined as the time elapsed from recruitment until the
date at which the data were censored for analysis.
Disease-related data gathered included SSc subtype
(diffuse or limited) defined according to the LeRoy cri-
teria [19]. The autoantibody status of each patient was
determined at recruitment using immunofluorescence
for antinuclear antibodies and commercially available
assays for antibodies to extractable nuclear antigens
Scl-70, Jo-1, ribonucleoprotein (RNP), Ro, La, Smith (Sm),
and polymyositis scleroderma (PM-Scl) (enzyme-linked
immunosorbent assay [ELISA]; ORGENTEC Diagnostika,
Mainz, Germany); antibodies to double-stranded DNA
(anti-dsDNA) (Amerlex radioimmunoassay; Trinity
Biotech, Bray, Ireland); antibodies to RNA polymerase
III (QUANTA Lite RNA Pol III; Inova Diagnostics, San
Diego, CA, USA; and MBL Anti-RNA Pol III; MBL
International, Woburn, MA, USA); anti-neutrophil
cytoplasmic antibodies (ANCA), including proteinase-3
or myeloperoxidase specificity (ELISA; ORGENTEC
Diagnostika); rheumatoid factor and anti-phospholipid
antibodies, including anti-cardiolipin antibodies (Vital
Diagnostics, Bella Vista, Australia); and anti-β2-glyco-
protein antibodies (ELISA; ORGENTEC Diagnostika).
Data collected at each annual visit
Disease manifestations were recorded at each visit.
Raynaud’s phenomenon was defined on the basis of
characteristic colour changes in the extremities. The pres-
ence of puffy digits (scleroderma), tendon friction rubs,
synovitis and muscle atrophy was based on examination
findings of the patient’s rheumatologist. The MRSS [20]
was also calculated and recorded at each visit.
Persistent sicca symptoms were defined as dry eyes or
dry mouth at two or more annual visits. Gastrointestinal
symptoms, including reflux requiring treatment withproton pump inhibitor, dysphagia, post-prandial bloating,
vomiting, diarrhoea (more than three motions per day),
constipation (fewer than one motion per day) or anal in-
continence (faecal soiling) not due to other causes, were
also recorded. Gastric antral vascular ectasia (GAVE) and
oesophageal stricture were defined on the basis of endos-
copy. Bowel dysmotility was defined on the basis of bar-
ium and nuclear medicine studies, antibiotic response and
characteristic symptoms. Pseudo-obstruction was defined
as the presence of clinical features suggestive of intestinal
obstruction in the absence of an anatomical lesion.
Myocardial disease was defined on the basis of endo-
myocardial biopsy or as the presence of conduction de-
fects, arrhythmias, and right ventricular or left ventricular
dysfunction on echocardiography in the absence of other
causes. Pericardial effusions were defined on the basis of
an echocardiogram showing other than a small (<1-cm
thickness), non-significant pericardial effusion.
PAH was defined on the basis of right heart
catheterization as a mean pulmonary arterial pressure ≥25
mmHg and a pulmonary arterial wedge pressure ≤15
mmHg. The 6-minute walk distance was also recorded
each year as a measure of PAH severity.
ILD was defined on the basis of characteristic changes
visualised by chest high-resolution computed tomog-
raphy. Pulmonary function tests were performed at each
annual visit, and forced vital capacity (FVC) and diffus-
ing capacity of the lung for carbon monoxide (DLCO)
were recorded as percent predicted values, with FVC
used as a measure of ILD activity and/or severity.
Renal crisis was defined as any two of the following
three criteria: new-onset severe hypertension (≥180 mmHg
systolic and/or ≥100 mmHg diastolic) without an alternate
aetiology, microangiopathic haemolytic anaemia, or rising
creatinine.
SSc treatment was recorded at each visit as follows:
corticosteroids (oral prednisolone), immunosuppressives
(leflunomide, methotrexate, azathioprine, penicillamine,
hydroxychloroquine, mycophenolate, cyclophosphamide
and calcineurin inhibitors), biologic therapies (tumour
necrosis factor-α inhibitors, tocilizumab, abatacept,
anti-CD20 antibodies and other B-cell modulators) and
home oxygen.
Definition of SSc overlap syndrome
The presence of ‘overlap disease’ was recorded at each
annual visit and was defined as evidence of SSc together
with characteristic symptoms or signs of overlap disease,
which included persistent sicca symptoms, episodes of
inflammatory myositis (muscle weakness together with
two or more of elevated serum creatinine kinase, charac-
teristic changes on electromyography and/or magnetic
resonance imaging, or muscle biopsy showing typical
histopathological changes), or a rheumatologist’s report
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rheumatoid arthritis, polymyositis, dermatomyositis, SLE
or Sjögren’s syndrome.
European Scleroderma Study Group disease activity score
The EScSG disease activity score and the presence of its
ten components were recorded at each visit: scleroderma;
digital necrosis; arthritis; MRSS >14; DLCO <80 % pre-
dicted; ESR >30 mm/h; hypocomplementaemia (low C3
and/or C4); and patient-reported changes in cardiopulmo-
nary, vascular or skin symptoms in the preceding month.
One point is assigned for the presence of each feature,
and scores can range from 0 to 10. However, because
hypocomplementaemia is one of the ten variables in the
EScSG activity score, we calculated a score based on
the other nine variables only, in order to avoid over-
correlation in subsequent analysis. Therefore, final
scores ranged from 0 to 9, with higher scores indicating
higher disease activity.
Physician global assessment
Physician global assessments of overall health, disease
activity and disease damage were also recorded prospect-
ively at each annual visit using a visual analogue scale.
Physician global assessments entail the physician’s taking
note of all the available clinical and laboratory informa-
tion in order to assign a score that ranges between 0
and 10 for each of overall health, disease activity and
disease-related damage. Higher scores represent worse
overall health, higher disease activity or greater disease-
related damage.
Statistical analysis
Descriptive statistics (mean ± SD, median [interquartile
range], minimum and maximum, and number [percent])
were used to describe the characteristics of the patients
and the data set. As there was <5 % missing data for any
particular variable, we did not impute missing data.
Univariable comparisons between patients who were
persistently normocomplementaemic during follow-up
and patients who had experienced at least one episode
of hypocomplementaemia during the course of the study
were made using the t test for continuous variables, the
chi-square test for categorical variables and the Wilcoxon
signed-rank test for ordinal variables. In this analysis,
disease manifestations were defined as ‘present ever’.
Additional analyses were performed comparing the two
groups described above (persistent normocomplementae-
mia and at least one episode of hypocomplementaemia)
with those who had persistent hypocomplementaemia at
every visit during follow-up.
In multivariable analyses, the association between
disease features at each visit and hypocomplementae-
mia at that particular visit was analysed. Here, we usedgeneralised estimating equations (GEEs) to account for
the expected correlation that arises when repeated mea-
surements are taken from the same individual at mul-
tiple visits over time [21]. Another advantage of this
method of analysis is that it overcomes any potential
misclassification error that might arise from dividing
patients into subgroups based on arbitrary definitions
such as hypocomplementaemia ever, persistent hypo-
complementaemia and persistent normocomplementae-
mia. Furthermore, as there is currently no consensus
regarding meaningful changes in clinical parameters
from one visit to the next, the use of GEEs enables
evaluation of the relationship between hypocomple-
mentaemia at a particular visit and actual clinical pa-
rameters at that particular visit.
All statistical analyses were performed using STATA
14 software (StataCorp, College Station, TX, USA). All
p values were two-tailed, and statistical significance was
defined as p ≤ 0.05. The overall study design and planned
analyses are presented in Fig. 1.
Results
This study included 1140 patients with SSc who had
complement levels recorded prospectively at one or
more visits.
Characteristics of cohort and data set
The cohort presented in this study is summarized in
Tables 1 and 2. Among the 1140 patients included in this
study, the average age of patients was 46.0 ± 14.1 years at
SSc diagnosis and 57.4 ± 12.3 years at recruitment, with a
mean follow-up time of 3.4 ± 1.7 years. In terms of demo-
graphics, 87.2 % of patients were female, 93.3 % were white,
4.7 % were Asian, 1.3 % were Australian Aboriginal or
Torres Strait Islander and 0.9 % were of other racial origin.
The mean disease duration at recruitment was 11.3 ±
9.9 years, with 14.3 % of patients having a disease dur-
ation ≤2 years and 31.2 % of patients having a disease dur-
ation ≤5 years at recruitment. Diffuse SSc was present in
27.2 % of patients, and 72.8 % of patients had limited SSc.
SSc overlap disease features were present in 23.4 % of
patients. The autoantibody profile of patients is summa-
rized in Table 1. Autoantibodies that were found in a
significant proportion of the cohort included anti-Scl-70
(15.2 %), anti-centromere (46.2 %), anti-RNA polymerase
(13.3 %), anti-dsDNA antibodies (13.3 %), ANCA
(12.9 %), rheumatoid factor (27.2 %), anti-phospholipid
(25.7 %) and anti-β2-glycoprotein (33.0 %) antibodies.
Characteristics of the data set pertaining to comple-
ment measurements are summarized in Table 3. Hypo-
complementaemia was present at recruitment in 13.2 %
of patients and thereafter present ever from recruitment
to most recent visit in 24.1 % of patients. The median
number of complement measurements per patient was 2,
Fig. 1 Study design. EScSG European Scleroderma Study Group, SSc Systemic sclerosis
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of measurements was 1, and the maximum number of
measurements was 8. The average time interval between
measurements was 1.2 ± 0.4 years. A total of 1893 individ-
ual visit measurements of complement with corresponding
clinical and serological data were available for analysis.
Univariable analyses
Univariable comparisons between patients who had
persistent normocomplementaemia during follow-up
and patients who had experienced at least one episode
of hypocomplementaemia during the course of the study
are summarized in Tables 4 and 5. Patients who had ever
been hypocomplementaemic were more likely to have
features of overlap disease present (29.5 % vs. 21.5 %,
p = 0.007), in particular polymyositis (1.8 % vs. 0.1 %,
p = 0.001). Hypocomplementaemia was also found to
be associated with a number of autoantibodies typically
associated with other rheumatic diseases, which included
anti-RNP (4.5 % vs. 1.2 %, p = 0.001), anti-Ro (10.8 % vs.
5.2 %, p = 0.001), anti-Sm (1.5 % vs. 0.2 %, p = 0.016) and
anti-phospholipid (31.3 % vs. 24.0 %, p = 0.02) antibodies.
Patients with hypocomplementaemia were also morelikely to have a BMI <20 kg/m2 (20.5 % vs. 13.0 %, p =
0.003), a feature of more active and severe gastrointestinal
involvement; scleroderma (72.8 % vs. 66.2 %, p = 0.044);
and muscle atrophy (23.2 % vs 17.2 %, p = 0.029). A
significant association with pericardial effusions (9.1 %
vs. 5.3 %, p = 0.023) was also found.
There was no difference in the mean EScSG disease
activity score or physician global assessment score for
overall health, disease activity and damage across all
visits in patients who were normocomplementaemic
compared with those who were hypocomplementaemic.
In additional analyses, we found no significant differences
between those who had at least one episode of hypocom-
plementaemia and persistent hypocomplementaemia
during follow-up, possibly due to very few patients in the
latter group (data not shown).
Multivariable regression analyses
In the analyses described above, variables were defined
as being ever present from disease onset to most recent
review. We performed a second series of analyses using
GEEs with data gathered at each visit. This set com-
prised a total of 1893 visits.
Table 1 Patient characteristics (n = 1140)
Characteristic n (%) or mean ± SD
Age at diagnosis, years 46.0 ± 14.1
Age at recruitment, years 57.4 ± 12.3
Follow-up duration, years 3.4 ± 1.7
Sex
Male 148 (13.0 %)
Female 992 (87.2 %)
Race
White 1012 (93.3 %)
Asian 50 (4.7 %)
Australian Aboriginal or Torres Strait Islander 14 (1.3 %)
Other 9 (0.9 %)
Disease duration at recruitmenta 11.3 ± 9.9
≤ 2 years 163 (14.3 %)
≤ 5 years 356 (31.2 %)
Disease subtypeb
Diffuse 310 (27.2 %)
Limited 830 (72.8 %)
Overlap disease features present everc 267 (23.4 %)
Rheumatoid arthritis 22 (1.9 %)
Polymyositis 6 (0.5 %)
Dermatomyositis 1 (0.01 %)
Sjögren’s syndrome 21 (1.8 %)
SLE 9 (0.8 %)
Serological profile at recruitment
Anti-centromere ANA 517 (46.2 %)
Anti-Scl-70 antibodies 167 (15.2 %)
Anti-RNAP antibodies 84 (13.3 %)
Anti-U1 RNP antibodies 22 (2.0 %)
Anti-Ro antibodies 72 (6.6 %)
Anti-La antibodies 18 (1.6 %)
Anti-Sm antibodies 6 (0.6 %)
Anti-PM-Scl antibodies 15 (1.4 %)
Anti-dsDNA antibodies 26 (3.1 %)
Anti-Jo-1 antibodies 5 (0.5 %)
ANCA 134 (12.9 %)
MPO specificity 17 (1.6 %)
PR-3 specificity 22 (2.1 %)
Rheumatoid factor 288 (27.2 %)
Anti-phospholipid antibodies 272 (25.7 %)
Cardiolipin IgM 165 (65.0 %)
Cardiolipin IgG 105 (39.3 %)
Anti-β2-glycoprotein antibody 84 (33.0 %)
Lupus anticoagulant 26 (3.1 %)
Abbreviations: ANA Anti-nuclear antibody, Anti-Scl-70 Anti-scleroderma-70 antibodies,
Anti-U1 RNP Anti-ribonucleoprotein antibodies, Anti-Sm Anti-Smith antibodies, Anti-
PM-Scl Anti-polymyositis scleroderma antibodies, Anti-dsDNA Anti-double-stranded
DNA antibodies, Anti-RNAP Anti-RNA polymerase antibodies, ANCA Anti-neutrophil
cytoplasmic antibodies, MPO Myeloperoxidase, PR-3 Proteinase-3
aSince onset of first non-Raynaud’s phenomenon disease manifestation
bDisease subtype based on extent of skin involvement, with limited disease
being confined to the extremities distal to elbows and knees, as well as the face
cActual overlap disease features specified for only a proportion of patients
classified by the treating physician as having ‘SSc overlap syndrome’
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specified an exchangeable working correlation structure
to account for the within-individual correlation and
computed robust standard errors on the parametric
estimates. We ran a univariable model of EScSG disease
activity score (with the complement component re-
moved to avoid over-correlation) and a multivariable
model containing all of the individual disease activity
variables listed in the EScSG disease activity index, with
the exception of the complement item, and with some
additional disease activity variables (C-reactive protein
[CRP] >8 mg/L and BMI) included on the basis of
univariable analyses (Table 6). Because scleroderma,
muscle atrophy and pericardial effusion, which were
statistically significant in univariable analysis, were not
statistically significant in multivariable analysis, these
variables were removed. Despite lack of significance in
a simple univariable comparison, in a multivariable
GEE model, FVC <80 % predicted was statistically sig-
nificant and therefore included in the final model. We
ran the multivariable models for (1) the whole cohort
(n = 886; 1893 visits in total) as well as (2) patients clas-
sified as having SSc overlap (n = 221; 628 visits in total)
and (3) those with non-SSc overlap (n = 665; 1265 visits
in total) (Table 6).
In the multivariable analysis using the entire cohort,
significant correlates of hypocomplementaemia at each
visit included a lower BMI (OR for BMI = 0.90, 95 % CI
0.88–0.94, p < 0.0005), a lower MRSS (OR for MRSS =
0.98, 95 % CI 0.96–0.99, p = 0.013) and a lower ESR (OR
for ESR = 0.99, 95 % CI 0.98–0.99, p = 0.022). In patients
with SSc overlap disease features, significant correlates
of hypocomplementaemia at each visit included digital
ulcers (OR = 1.62, 95 % CI 1.04–2.51, p = 0.034), tendon
friction rubs (OR = 2.31, 95 % CI 1.05–5.10, p = 0.037),
an FVC <80 % predicted (OR = 2.90, 95 % CI 1.32–6.38,
p = 0.008) and a lower BMI (OR for BMI = 0.90, 95 % CI
0.85–0.95, p < 0.0005), all variables that are associated
with increased SSc disease activity and/or severity. In
patients without overlap disease features, significant
correlates of hypocomplementaemia at each visit included
a lower BMI (OR for BMI = 0.91, 95 % CI 0.87–0.95,
p < 0.0005) and a lower ESR (OR for ESR = 0.99, 95 %
CI 0.97–0.99, p = 0.026).
Discussion
In this longitudinal cohort study of 1140 patients with
SSc, we found that low serum complement occurred at
least once in 23.4 % of patients over the study period.
We also found that these patients were more likely to
have SSc overlap disease features than patients who were
normocomplementaemic (29.5 % vs. 21.5 %, p = 0.007),
in particular polymyositis. We have also demonstrated
that hypocomplementaemia is not a measure of disease
Table 2 Disease manifestations in cohort (n = 1140)
Characteristics n (%) or median (25th–75th IQR)
Disease manifestationa
Raynaud’s phenomenon 1065 (94.0 %)
Digital ulcers 345 (30.5 %)
Digital gangrene/amputation 93 (8.2 %)
Telangiectasia 947 (83.8 %)
Calcinosis 439 (38.9 %)
Scleroderma 763 (67.8 %)
Tendon friction rub 112 (10.0 %)
Joint contracture 431 (38.3 %)
Synovitis 323 (28.7 %)
Muscle atrophy 210 (18.7 %)
MRSS score >20 207 (18.5 %)
Myocardial disease 87 (7.6 %)
Pericardial effusionb 70 (6.2 %)
PAHc 298 (26.9 %)
ILDd 340 (30.1 %)
Gastrointestinal involvemente 638 (56.3 %)
GAVE 113 (10.0 %)
Reflux oesophagitis 958 (84.3 %)
Oesophageal stricture 207 (18.3 %)
Oesophageal dysmotility 457 (40.6 %)
Bowel dysmotility 297 (26.3 %)
Pseudo-obstruction 37 (3.3 %)
Renal crisesf 44 (3.9 %)
eGFR <60 ml/minute 297 (26.4 %)
Myositisg 58 (6.0 %)
CRP >8 mg/L 333 (29.7 %)
ESR >30 mm/h 323 (28.8 %)
Blood CK >200 IU/L 122 (11.0 %)
Anaemiah 403 (35.5 %)
FVC <80 % predicted 298 (26.9 %)
DLCO <80 % predicted 832 (79.9 %)
EScSG disease activity scorei 2.5 (1–4)
Treatmentsa
Corticosteroids 506 (44.4 %)
Immunotherapyj 495 (43.4 %)
Biological therapyk 16 (1.4 %)
Home oxygen 41 (3.6 %)
Table 2 Disease manifestations in cohort (n = 1140) (Continued)
Physician global assessmentsl
Overall healthm 4 (3–6)
Activityn 3 (2–5)
Damagen 4 (3–6)
Abbreviations: MRSS Modified Rodnan skin score, EScSG European Scleroderma
Study Group, PAH Pulmonary arterial hypertension, ILD Interstitial lung disease,
GAVE Gastric antral vascular ectasia, eGFR Estimated glomerular filtration rate,
CRP C-reactive protein, ESR Erythrocyte sedimentation rate, CK Creatinine kinase,
FVC Forced vital capacity, DLCO Diffusing capacity of the lung for carbon monoxide
corrected for haemoglobin
aEver from disease onset to most recent visit
bPericardial effusion defined by echocardiography
cPAH defined by right heart catheterization with a mean pulmonary artery
pressure ≥25 mmHg and a pulmonary arterial wedge pressure ≤15 mmHg
dPulmonary fibrosis defined by chest high-resolution computed tomography
eGastrointestinal symptoms defined as the presence of any of reflux,
dysphagia, post-prandial bloating, vomiting, constipation, diarrhoea or anal in-
continence as defined in text
fRenal crisis defined as the presence of at least two of the following: new-onset
hypertension, rising creatinine or microangiopathic haemolytic anaemia
gMyositis defined as either definite (biopsy), suspected (CK or electromyogram)
or possible (magnetic resonance imaging scan)
hAnaemia defined as haemoglobin level <135 g/L in males and <120 g/L
in females
iCalculated without hypocomplementaemia. Final scores range from 0 to 9,
with higher scores indicating higher disease activity
jIncludes leflunomide, methotrexate, azathioprine, penicillamine, hydroxychloroquine,
mycophenolate, cyclophosphamide and calcineurin inhibitors
kIncludes tumour necrosis factor alpha inhibitors, tocilizumab, abatacept, anti-CD20
antibodies and other B-cell modulators
lHighest score ever recorded over the study period
mScores range from 0 to 10, with higher scores being indicative of worse
overall health
nScores range from 0 to 10, with higher scores being indicative of higher
disease activity or damage
Table 3 Characterisation of complement levels (n = 1140)
Parameter n (%) or mean ± SD or median
(25th–75th IQR)
Hypocomplementaemiaa
At recruitment 150 (13.2 %)




1 400 (35.1 %)
2 265 (23.3 %)
3 196 (17.2 %)
4 129 (11.3 %)
5 85 (7.5 %)
6 50 (4.4 %)
7 14 (1.2 %)
8 1 (0.1 %)
Total number of complement
measurements in data set
1893
Time interval between complement
measurements, years
1.2 ± 0.4
aA low C3 and/or C4 result
bAt least one episode of hypocomplementaemia over the study period
Esposito et al. Arthritis Research & Therapy  (2016) 18:246 Page 7 of 12
Table 4 Univariable comparison of demographics, disease subtypes and serological profiles in patients with persistent
normocomplementaemia and those with at least one episode of hypocomplementaemia
Characteristic Persistent normocomplementaemia (n = 865) At least one episode of hypocomplementaemia (n = 275)
n (%) or mean ± SD or median (IQR) n (%) or mean ± SD or median (IQR) p Value
Age at diagnosis, years 46.4 ± 0.5 44.6 ± 0.8 0.071
Sex
Male 113 (13.1 %) 35 (12.7 %) 0.89
Female 752 (86.9 %) 240 (87.3 %) 0.89
Disease duration 11.3 ± 0.4 11.6 ± 0.7 0.71
≤ 2 years 117 (14.5 %) 46 (17.5 %) 0.24
≤ 5 years 268 (33.2 %) 88 (33.5 %) 0.94
Disease type
Diffuse 238 (27.5 %) 72 (26.2 %) 0.67
Limited 627 (72.5 %) 203 (73.8 %) 0.67
Overlap features presenta 186 (21.5 %) 81 (29.5 %) 0.007
Rheumatoid arthritis 15 (1.7 %) 7 (2.6 %) 0.39
Polymyositis 1 (0.1 %) 5 (1.8 %) 0.001
Dermatomyositis 0 (0 %) 1 (0.4 %) 0.076
Sjögren’s syndrome 14 (1.6 %) 7 (2.6 %) 0.32
SLE 6 (0.7 %) 3 (1.1 %) 0.52
Serological profilea
Anti-centromere ANA 391 (46.0 %) 126 (47.0 %) 0.084
Anti-Scl-70 antibodies 134 (16.1 %) 33 (12.3 %) 0.13
Anti-Jo-1 antibodies 4 (0.5 %) 1 (0.4 %) 0.82
Anti-RNP antibodies 10 (1.2 %) 12 (4.5 %) 0.001
Anti-Ro antibodies 43 (5.2 %) 29 (10.8 %) 0.001
Anti-La antibodies 12 (1.5 %) 6 (2.2 %) 0.38
Anti-Sm antibodies 2 (0.2 %) 4 (1.5 %) 0.016
Anti-PM-Scl antibodies 10 (1.2 %) 5 (1.9 %) 0.43
Anti-dsDNA antibodies 16 (2.5 %) 10 (4.9 %) 0.089
Anti-RNAP antibodies 61 (13.6 %) 23 (12.6 %) 0.74
ANCA 95 (12.1 %) 39 (15.2 %) 0.20
MPO specificity 14 (1.8 %) 3 (1.2 %) 0.50
PR-3 specificity 14 (1.8 %) 8 (3.1 %) 0.20
Rheumatoid factor 208 (26.1 %) 80 (31.3 %) 0.11
Anti-phospholipid antibodies 192 (24.0 %) 80 (31.3 %) 0.02
Cardiolipin IgM 115 (63.2 %) 50 (69.4 %) 0.351
Cardiolipin IgG 78 (41.5 %) 27 (34.2 %) 0.26
β2-glycoprotein 59 (32.8 %) 25 (33.3 %) 0.93
Lupus anti-coagulant 15 (2.4 %) 11 (5.0 %) 0.056
Abbreviations: ANA Anti-nuclear antibody, Anti-Scl-70 Anti-scleroderma-70 antibodies, Anti-RNP Anti-ribonucleoprotein antibodies, Anti-Sm Anti-Smith antibodies,
Anti-PM-Scl Anti-polymyositis scleroderma antibodies, Anti-dsDNA Anti-double-stranded DNA antibodies, Anti-RNAP Anti-RNA polymerase antibodies, ANCA
Anti-neutrophil cytoplasmic antibodies, MPO Myeloperoxidase, PR-3 Proteinase-3, Ig Immunoglobulin, SLE Systemic lupus erythematosus
aEver from disease onset to most recent visit
Esposito et al. Arthritis Research & Therapy  (2016) 18:246 Page 8 of 12activity when applied across the entire cohort of patients
with SSc. However, to our knowledge, this is the first
study to demonstrate that hypocomplementaemia is a
marker of the presence of certain SSc disease featuresmeasured at each visit among the subset of patients with
overlap disease features. These disease features include
digital ulcers, tendon friction rubs, low BMI and low
FVC, all of which are clinical features of SSc disease
Table 5 Univariable associations of hypocomplementaemia with clinical manifestations, treatment, European Scleroderma Study
Group disease activity score and physician global assessments
Characteristic Persistent normocomplementaemia (n = 859) At least one episode of hypocomplementaemia (n = 275)
n (%) or mean ± SD or median (IQR) n (%) or mean ± SD or median (IQR) p Value
Disease manifestationa
Raynaud’s phenomenon 803 (93.5 %) 262 (95.6 %) 0.19
BMI <20 kg/m2 104 (13.0 %) 54 (20.5 %) 0.0030
Digital ulcers 263 (30.7 %) 82 (30.0 %) 0.848
Digital gangrene/amputation 76 (8.8 %) 17 (6.2 %) 0.17
Telangiectasia 716 (83.6 %) 231 (84.6 %) 0.68
Calcinosis 340 (39.7 %) 99 (36.3 %) 0.31
Scleroderma 565 (66.2 %) 198 (72.8 %) 0.044
Tendon friction rub 88 (10.3 %) 24 (8.8 %) 0.47
Joint contracture 332 (38.9 %) 99 (36.4 %) 0.46
Synovitis 241 (28.3 %) 82 (30.0 %) 0.59
Muscle atrophy 147 (17.2 %) 63 (23.2 %) 0.029
MRSS >20 158 (18.7 %) 49 (18.0 %) 0.81
Myocardial disease 70 (8.1 %) 17 (6.2 %) 0.30
Pericardial effusion 45 (5.3 %) 25 (9.1 %) 0.023
PAH 90 (10.4 %) 30 (10.9 %) 0.82
Pulmonary fibrosis 263 (30.8 %) 77 (30.1 %) 0.40
Gastrointestinal involvement 493 (57.5 %) 145 (52.7 %) 0.17
GAVE 86 (10.1 %) 27 (9.9 %) 0.94
Reflux oesophagitis 722 (83.8 %) 236 (85.8 %) 0.41
Oesophageal stricture 109 (12.8 %) 23 (8.4 %) 0.051
Oesophageal dysmotility 346 (40.5 %) 111 (40.8 %) 0.92
Bowel dysmotility 226 (26.4 %) 71 (25.9 %) 0.88
Pseudo-obstruction 25 (2.9 %) 12 (4.4 %) 0.23
Renal crises 36 (4.2 %) 8 (2.9 %) 0.34
eGFR <60 ml/minute 229 (22.8 %) 68 (25.0 %) 0.55
Myositis 37 (5.2 %) 21 (8.5 %) 0.055
CRP >8 mg/L 266 (31.1 %) 67 (24.9 %) 0.051
ESR >30 mm/h 252 (29.6 %) 71 (26.1 %) 0.27
Blood CK >200 IU/L 105 (12.1 %) 44 (16.0 %) 0.098
Anaemia 302 (35.1 %) 101 (36.7 %) 0.62
FVC <80 % 225 (26.9 %) 73 (27.0 %) 0.97
DLCO <80 % 631 (80.5 %) 201 (78.2 %) 0.43
Treatmenta
Corticosteroids 380 (43.9 %) 126 (45.8 %) 0.58
Immunotherapy 364 (42.1 %) 131 (47.6 %) 0.11
Biologic therapy 9 (1.0 %) 7 (2.6 %) 0.065
Home oxygen 32 (3.7 %) 9 (3.3 %) 0.74
EScSG scoreb 2.5 (1.4) 2 (1–4) 0.16
Physician global assessmentsb
Health 4 (3–6) 4 (3–6) 0.25
Activity 3 (2–5) 3 (2–5) 0.076
Damage 4 (2.5–6) 4 (3–6) 0.44
Abbreviations: MRSS Modified Rodnan skin score, EScSG European Scleroderma Study Group, PAH Pulmonary arterial hypertension, ILD Interstitial lung disease,
GAVE Gastric antral vascular ectasia, BMI Body mass index, eGFR Estimated glomerular filtration rate, CRP C-reactive protein, ESR Erythrocyte sedimentation rate,
CK Creatinine kinase, FVC Forced vital capacity, DLCO Diffusing capacity of the lung for carbon monoxide corrected for haemoglobin
aEver from disease onset to most recent visit
bMean score from all visits
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Table 6 Multivariable associations of hypocomplementaemia with features of disease activity at each visit among the whole cohort
and analysis subsets determined using generalised estimating equations
Whole cohort
(n = 886; 1893 visits)
SSc with features of overlap
disease (n = 221;628 visits)
SSc without features of overlap
disease (n = 665; 1265 visits)
Parameter Odds ratio
(95 % CI)
p Value Odds ratio
(95 % CI)
p Value Odds ratio
(95 % CI)
p Value
Self-reported worsening of cardiopulmonary,
vascular or skin symptomsa
1.05 (0.57–1.94) 0.87 1.24 (0.48–3.18) 0.66 1.03 (0.45–2.35) 0.94
Digital ulcers/necrosisa 1.15 (0.84–1.56) 0.38 1.62 (1.04–2.51) 0.034 0.82 (0.53–1.27) 0.37
Sclerodermaa 0.97 (0.76–1.23) 0.78 1.08 (0.75–1.58) 0.67 0.87 (0.63–1.18) 0.37
Tendon friction rubsa 1.15 (0.64–2.08) 0.64 2.31 (1.05–5.10 0.037 0.54 (0.19–1.53) 0.24
Synovitis/arthritisa 0.95 (0.69–1.31) 0.76 1.18 (0.73–1.91) 0.50 0.80 (0.51–1.25) 0.32
Modified Rodnan skin score >14a 0.98 (0.96–0.99) 0.013 0.97 (0.95–1.01) 0.087 0.98 (0.96–1.01) 0.16
Erythrocyte sedimentation rate >30 mm/ha 0.98 (0.98–0.99) 0.022 0.99 (0.99–1.01) 0.97 0.99 (0.97–0.99) 0.026
DLCO <80 % predicteda 0.81 (0.61–1.09) 0.17 1.14 (0.66–1.96) 0.65 0.72 (0.51–1.03) 0.073
C-reactive protein >8 mg/La 1.01 (0.99–1.01) 0.90 0.97 (0.93–1.01) 0.073 1.01 (0.99–1.01) 0.41
BMIb 0.91 (0.88–0.94) <0.0005 0.90 (0.85–0.95) <0.0005 0.91 (0.87–0.95) <0.0005
FVC <80 % predictedb 1.24 (0.78–1.97) 0.37 2.90 (1.32–6.38) 0.0080 0.87 (0.47–1.61) 0.65
Abbreviations: BMI Body mass index, FVC forced vital capacity, DLCO Diffusing capacity of the lung for carbon monoxide corrected for haemoglobin
All variables listed in the table were included in the final multivariable generalised estimating equation model
aComponents of European Scleroderma Study Group disease activity index
bAdditional disease activity variables entered into multivariable regression model on the basis of significance in univariable analysis
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urement of C3 and C4 in assessment and monitoring of
disease activity in patients with overlap SSc.
We found that the prevalence of hypocomplementaemia
at recruitment was 13.2 %, which is consistent with previous
smaller studies [22, 23]. The finding that hypocomplemen-
taemia is associated with the presence of overlap disease fea-
tures in SSc is also consistent with trends identified by
Hudson et al. in a cohort of 321 Canadian patients with SSc
[23]. This suggests that complement consumption plays a
significant role in the etiopathogenesis of SSc overlap disease.
Several small studies have cited a role for abnormal
complement activation in SSc. Senaldi et al. found that
the levels of serum complement fragments Ba, C3d and
C4d were higher in patients with diffuse SSc than in
patients with limited SSc and that both subtypes had
serum complement fragment levels higher than those
of normal patients, suggesting that complement con-
sumption occurs in SSc and may also be related to dis-
ease activity and/or severity [24]. Batal et al. undertook
a study of prognostic factors in systemic sclerosis renal
crisis (SRC) in which they retrospectively analysed
renal biopsies. They found that peritubular capillary
C4d deposition was higher in patients with SRC than
in both hypertensive non-SRC and normotensive non-
SRC control subjects and suggested a role for immune
complex- and antibody-mediated injury in SRC [25].
Whilst in vivo activation of the complement system in
SSc remains a possibility, the general consensus is that
complement consumption does not play a significant
role in the pathophysiology of SSc and that thereforethe presence of hypocomplementaemia in SSc signifies
the presence of another overlapping disease. This is
consistent with the results of our study, which demon-
strated a significant association between hypocomple-
mentaemia and the presence of SSc overlap disease, in
particular polymyositis. However, it is intriguing to
note that even among patients with overlap disease,
low serum complement was associated with disease
features classically associated with SSc itself, such as
digital ulcers and tendon friction rubs.
Hypocomplementaemia is one of the ten variables
listed in the EScSG disease activity index [26, 27]. How-
ever, its inclusion has been a point of controversy. In the
present study, we were unable to demonstrate a consistent
association between hypocomplementaemia and either
the EScSG disease activity score (calculated on the basis of
nine non-complement variables to avoid over-correlation
between independent variables) or any of its component
variables in the univariable analysis. In addition, the asso-
ciations found in the multivariable analysis in the subset
of patients with SSc without overlap disease features
(non-overlap SSc) suggest that, compared with normo-
complementaemic patients, hypocomplementaemic pa-
tients have lower EScSG disease activity scores and ESR
levels, which is the opposite of what one might expect.
This lack of expected correlation with SSc disease activity
measures suggests that hypocomplementaemia is not a
measure of disease activity in the majority of patients with
SSc, which is consistent with the conclusions drawn from
previous studies [23]. Only one study suggested the con-
trary. Cuomo et al. reported the associations between
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302 Italian patients with SSc and excluded patients with
overlap disease features. They found that 16.5 % of their co-
hort had hypocomplementaemia and that hypocomplemen-
taemia was associated with significantly increased disease
activity, significantly increased severity of disease manifesta-
tions in the skin, cardiovascular and respiratory systems,
and greater functional disability [22]. However, it is unclear
whether the results of their study are generalizable to other
SSc cohorts, because there was a very high prevalence of
patients with anti-Scl-70 and anti-centromere ANA. The
latter autoantibodies in particular have been suggested to
play a role in complement activation [28].
The lack of association between hypocomplementae-
mia and other potential markers of disease activity in
the EScSG disease activity index may also speak to the
latter’s not being a very good measure of ‘disease activity’
per se. A trend toward a significant difference in the
physician global assessment of disease activity between
the persistently normocomplementaemic and the hypo-
complementaemic groups (p = 0.076) supports this state-
ment. However, it is also possible that each item in the
EScSG disease activity index measures disease activity
independently of all other items. Furthermore, it must
be noted that functional abnormalities in complement in
SSc may occur in the absence of hypocomplementaemia.
To our knowledge, this is the first study to use GEE
methods to definitively show that hypocomplementae-
mia is associated with some features of disease activity
in patients with SSc who have overlap disease features.
We found that within this subset of patients with SSc,
those who were hypocomplementaemic were more likely
to manifest digital ulcers, tendon friction rubs, an FVC
<80 % predicted and a lower BMI at each visit, all of
which are well-established features of disease activity
and severity in non-overlap SSc itself. No association
was found with either CRP or ESR, possibly because
these inflammatory markers generally are not considered
to be good measures of disease activity in SSc. In par-
ticular, it has been shown that CRP levels are not elevated
in most patients with SSc and that CRP levels regress as
disease duration increases [29].
This study is not without limitations. As patients had
varying lengths of follow-up, some had more annual
complement measurements than others, making it
possible that there was a low complement reading by
chance alone on one or more occasions. However, the
use of GEEs for statistical analysis overcomes this issue
to a degree because it enables hypocomplementaemia at
each visit to be associated with disease features at that
particular visit, eliminating the need to divide patients
into subgroups based on arbitrary definitions such as
hypocomplementaemia ever, persistent hypocomplemen-
taemia and persistent normocomplementaemia.Conclusions
In this study, we have shown that hypocomplementaemia
in SSc is associated with the presence of SSc overlap fea-
tures, in particular SSc-polymyositis overlap syndrome.
We have also confirmed the results of previous studies by
showing that hypocomplementaemia is not a measure of
disease activity in non-overlap SSc cohorts. However, to
our knowledge, this is the first study to show that hypo-
complementaemia is associated with features of disease
activity in SSc overlap disease and that, in these pa-
tients, the measurement of complement levels is
potentially useful for monitoring disease activity and
response to treatment.
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